Arteriosclerosis
45 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| "Trained Eye" (Angiography-Guided) LM PCI for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 Stent for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 2 Stents for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aroxxen for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BiOSS LIM C for coronary artery disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calf Plantar flexion + Dietary nitrate for peripheral arterial disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Canakinumab for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for atherosclerosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg + Usual Care Group for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Coronary Sinus Reducer for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| EA-230 90mg/kg/hour for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for arteriosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Essential Pro Paclitaxel Drug-Eluting Balloon for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Intensified medical follow-up and glucose-lowering drugs for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left main stenting with intravascular lithotripsy for atherosclerosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left main stenting with intravascular lithotripsy for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lepodisiran for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lepodisiran Sodium for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maridebart Cafraglutide for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Muvalaplin for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polycap for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qidan Xiaoke Granules + Standard Medical Therapy for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Regadenoson for coronary artery disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for peripheral arterial disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Selnoflast for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tertinat for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tertinat for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| VERVE-102 for atherosclerosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Very-short DAPT less than 1 month after PCI for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YMI024 for coronary artery disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziltivekimab for atherosclerosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ziltivekimab for coronary artery disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zotarolimus-eluting stent (Endeavor Resolute) for coronary artery disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |